This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

John McCafferty, PhD
Department of Medicine, University of Cambridge and CEO at Maxion Therapeutics

Profile

John McCafferty was a co-inventor of antibody phage display and one of the founders of Cambridge Antibody Technology (CAT) which was acquired by Astra Zeneca in 2006. In 2012 he formed IONTAS, an innovative biotechnology company using phage display to develop novel antibody therapeutics. During this period John developed IONTAS’s proprietary mammalian display technology.

John is also an inventor of a novel molecular fusion format (KnotBodyTM) wherein naturally occurring, venom-derived cysteine-rich peptides are inserted into peripheral CDR loops of an antibody. He recently formed Maxion Therapeutics to take advantage of this drug development opportunity with a particular focus on modulation of ion channels and GPCRs.

In spring 2022 John returned to academia at the Department of Medicine, University of Cambridge to develop recombinant antivenoms for sub-Saharan Africa

John McCafferty, PhD's Network

Agenda Sessions

  • Can We “Deconvolute” Polyclonal Antivenoms to Create Defined Recombinant Antibody Cocktails?

    16:15